Johnson & Johnson Pledges USD55 Billion for US Expansion, Focusing on Manufacturing and R&D
US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55...
J&J
Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the...
Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from...
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting...
Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...
Johnson & Johnson Officially Launches Spravato in China for Depression Treatment
US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in...
GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...
J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval...
J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...
J&J Considers Selling Stroke Care Business Cerenovus for USD1-1.5 Billion
US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care...
J&J Innovative Medicine China Appoints New General Manager and Oncology VP
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments...
J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China
US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s...
EMA Committee Backs Subcutaneous Rybrevant for Lung Cancer Treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Johnson & Johnson Reports Q4 Growth, Projects 2025 Sales Outlook
US-based Johnson & Johnson (J&J, NYSE: JNJ) has released its Q4 2024 financial results, reporting...
Johnson & Johnson’s Spravato Approved as Monotherapy for Major Depressive Disorder
US-based Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Spravato (esketamine) CIII nasal...
Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced the initiation of the submission of...
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B
US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of...
HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics
China-based Hangzhou HealZen Therapeutics Co., Ltd., in collaboration with the Shanghai Institute of Materia Medica,...
NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma
China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR...
FDA Grants Priority Review to Johnson & Johnson’s Nipocalimab for Myasthenia Gravis
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced that the US FDA has granted...